Clinical Trial

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 6, 2023 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the clinical efficacy and safety of Tislelizumab (one anti-PD-1 antibody same as nivolumab approved in China) in combination with bevacizumab in patients with recurrent or progressive glioblastoma (GBM) who have progressed on bevacizumab with or without PTEN or TERT gene mutations.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-09-11; most recent amendment 2023-10-04.
Status change: Recruiting → Not Yet Recruiting 2022-09-25
Trial Details
NCT Number NCT05540275
Lead Sponsor Henan Provincial People's Hospital
Conditions Recurrent Glioblastoma
Enrollment 30 participants
Start Date 2023-10-05
Primary Completion 2024-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2023-10-06